Stopping prostate cancer from becoming invasive
Preventing invasive prostate cancer
This project develops a new drug called KBU2046 that aims to stop early prostate cancer cells from moving so they don't become invasive in men at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11158737 on NIH RePORTER |
What this research studies
Researchers will use chemical probes, protein-mapping tools, and computer modeling to find exactly where KBU2046 binds on cancer-related proteins. They will map how the Raf1 signaling pathway and its partners (including HSP90β and CDC37) control prostate cell movement and show how KBU2046 changes that signaling. The team will also complete safety and drug-development studies in cells and animal models that are needed before human testing. These steps are intended to support future clinical trials of KBU2046 as a prevention or interception therapy.
Who could benefit from this research
Good fit: Men with early-stage or localized prostate cancer or those judged at high risk for developing invasive prostate cancer would be the most likely candidates for future trials.
Not a fit: People with already advanced or widespread metastatic prostate cancer are unlikely to benefit from this prevention-focused approach.
Why it matters
Potential benefit: If successful, this work could prevent early prostate cancers from invading nearby tissue and lower the chance of dying from advanced disease.
How similar studies have performed: This is a novel, first-in-class approach—selective blockers of tumor cell motility have shown promise in lab and animal tests but have not yet been proven in humans.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Bergan, Raymond C. — University of Nebraska Medical Center
- Study coordinator: Bergan, Raymond C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.